share_log

VIVXF: OxC-beta Approved in Vietnam…

VIVXF: OxC-beta Approved in Vietnam…

VIVXF:越南批准OXC-BETA…
Benzinga Real-time News ·  2022/05/09 10:16
By David Bautz, PhD
作者:David Bautz博士
OTC:VIVXF
場外交易:VIVXF
READ THE FULL VIVXF RESEARCH REPORT
閲讀完整的VIVXF研究報告
Business Update
商業動態
OxC-beta Approved in Vietnam; Looking for Sales Ramp in 2H22
OXC-Beta在越南獲批;尋求在2小時22秒內實現銷售增長
Avivagen, Inc. (OTC:VIVXF) is developing products to support animal health, which includes replacing antibiotics in livestock feeds with proprietary compounds that promote the growth and overall health of the animal through support of the host's innate immune system. Avivagen discovered that β-carotene polymerizes with oxygen into a unique class of compounds (oxidized β-carotene, OxBC) that promote immunological health and are the basis of Avivagen's OxC-beta™ technology. Numerous studies conducted by Avivagen and...
Avivagen,Inc.(場外交易代碼:VIVXF)正在開發支持動物健康的產品,其中包括用專有化合物取代牲畜飼料中的抗生素,這些化合物通過支持宿主的先...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論